The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities

Jianfei Qi; Maurizio Pellecchia; Ze’ev A. Ronai

doi:10.18632/oncotarget.171

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities

Jianfei Qi, Maurizio Pellecchia and Ze’ev A. Ronai _

PDF | HTML | How to cite

Oncotarget. 2010; 1:379-385. https://doi.org/10.18632/oncotarget.171

Metrics: PDF 3089 views | HTML 3777 views | ?

Abstract

Received: August 17, 2010, Accepted: September 18, 2010, Published: September 24, 2010

Recent studies indicate the importance of the ubiquitin ligase Siah2 in control of more aggressive prostate tumors – namely, neuroendocrine (NE) prostate tumors and prostate adenocarcinoma (PCa) harboring neuroendocrine lesions. Siah2-dependent expression and activity of HIF-1α regulate its availability to form a transcriptional complex with FoxA2, resulting in expression of specific target genes, including Hes6, Sox9 and Jmjd1a, whose co-expression is sufficient for formation of NE tumors and NE lesions in PCa. These studies provide novel markers to diagnose and monitor formation of NE lesions and NE tumors. Furthermore, defining the regulatory axis consisting of Siah2 and HIF-1α/FoxA2 cooperation suggests novel therapeutic modalities to treat these most aggressive forms of prostate cancer. Here we review current understanding of Siah role in control of hypoxia and prostate tumor development and highlight potential approaches for targeting components along Siah-regulated pathways.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 171

Publication Alerts

Research Perspectives:

The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities

Abstract